Nexstim Members Of The Board Committees

Published: Jun 05, 2017

Company announcement, Helsinki, 5 June 2017 at 2:00 pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, announces that the Board of Directors of Nexstim Plc has decided that Tomas Holmberg shall replace Martin Jamieson in the Remuneration Committee. Risto Ilmoniemi and Juliet Thompson were elected as new members of the Nomination committee. After these changes mentioned above the Nexstim Plc Board Committee members are as follows:

The chairman of the Audit Committee shall be Juliet Thompson and the members shall be Rohan J. Hoare and Tomas Holmberg.

The chairman of the Remuneration committee shall be Ken Charhut and the members shall be Rohan J. Hoare and Tomas Holmberg.

The chairman of the Nomination Committee shall be Sami Tuhkanen and the members shall be Risto Ilmoniemi and Juliet Thompson.

NEXSTIM PLC
Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by telephone:

Nexstim +447715163942
Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com

UB Securities Oy (Certified Adviser) +358 (0)9 2538 0246

Citigate Dewe Rogerson +44 (0)207 2821066
Katja Stout katja.stout@citigatedr.co.uk

About Nexstim Plc
Nexstim is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain.

Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked for the treatment of stroke, major depression and chronic neuropathic pain. The NBT® system is currently in a supplemental Phase III study, E-FIT trial, which will recruit 60 patients. The trial is expected to complete in Q2 2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/dfb5ce31-8324-4810-b1ad-5fcbd29ef7c9

Back to news